$10 billion worth of settlements for Bayer

$10 billion worth of settlements for Bayer

Bayer to pay more than $10 billion in Roundup lawsuit settlements

While the world pays attention to the new wave of infections, and some pharma companies are rallying to find a cure, others face distinct problems such as cancer claims and lawsuits. One of the largest pharmaceutical companies globally, Bayer, hit the news as it has to pay $10.9 billion in settlements due to one of its products.

The amount will go to approximately 100,000 people who claim that one of its herbicides, Roundup, causes cancer. Roundup was initially the product of the US company Monsanto, which has been bought by Bayer in 2018 for $63 billion. For more than 40 years, the product became the world’s most famous weedkiller. The lawsuits revealed that Monsanto intentionally put aside the warnings that the herbicide has potential cancer-causing chemicals, and hid it from the consumers. The herbicide that caused complainants non-Hodgkin’s lymphoma and other sorts of cancers, glyphosate, is not a carcinogen from Bayer's point of view. The US Environmental Protection Agency supports its statement.

The German giant will pay up to $9.6 billion to settle the ongoing lawsuits and $1.25 billion to cover any possible litigation that could come up in the future. The money will be paid in two installments: $5 billion by the end of this year, and the rest in 2021. Moreover, Bayer is to pay $820 million in cases related to water pollution caused by a chemical compound polychlorinated biphenyl – now banned. And for another banned herbicide, it will pay from its pocket another $400 million.

After it was reported that Bayer would pay the settlements, the stock price climbed 6%; it lost more than 2% during today's session.

Read more about the pharmaceutical companies by accessing our Market News section!

Sources: bbc.com, nbcnews.com, media.bayer.com


تولت CAPEX.com إعداد المعلومات الواردة هنا دون أن تقصد من ورائها تقديم نصيحة استثمارية. تُقدم المعلومات المذكورة هنا باعتبارها تعليق عام على السوق لأغراض إعلامية فحسب، وبالتالي لم يتم إعدادها وفقاً للمتطلبات القانونية الهادفة لتعزيز استقلالية بحوث الاستثمار، وعليه لا تخضع لأي حظر على التعامل عليها قبل نشر الأبحاث الاستثمارية.

لا يجب على المستخدمين/القراء الاعتماد على المعلومات المقدمة هنا وحدها ويجب على المتلقي إجراء تحليلاته/أبحاثه الخاصة عن طريق قراءة البحث الأساسي الفعلي.تتسم المعلومات الواردة هنا بالعمومية ولا تأخذ في الاعتبار الظروف الشخصية لكل فرد، أو خبراته الاستثمارية أو وضعه المالي الحالي.

وبناء عليه، لن تتحمل Key Way Investments Ltd الأداء السابق للأصل المالي وتوقعات الأسواق ليست مؤشرات موثوقة للنتائج المستقبلية. لا يعتبر الأداء السابق مؤشراً موثوقاً على النتائج المستقبلية.